GlassScriptPhysician profile
Gary R Cohan
NPI 1952450769
$4,390.81
in general payments reported to CMS, 2019-2025
28 companies · $941 in 2025
The $941 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $322 · 2021: $236 · 2022: $222 · 2023: $731 · 2024: $1,092 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $795.34 | 2019-2025 | Apretude, Rukobia |
| Gilead Sciences, INC. | $693.45 | 2019-2025 | |
| Amgen INC. | $657.04 | 2019-2025 | Repatha, Otezla, Otezla |
| Daiichi Sankyo INC. | $402.48 | 2019-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $300.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $199.46 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Lilly USA, LLC | $182.91 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.37 | 2019-2023 | Xifaxan |
| Dexcom, INC. | $156.78 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $95.31 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $83.27 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $67.50 | 2019-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $65.62 | 2023-2025 | Cologuard Collection Kit |
| Heartflow, INC. | $64.48 | 2022-2024 | Ffrct |
| Novo Nordisk INC | $54.36 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.69 | 2021-2022 | |
| Abbott Laboratories | $46.62 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $43.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.70 | 2023 | Trintellix |
| Allergan, INC. | $35.41 | 2019 | |
| Genentech USA, INC. | $34.06 | 2019 | |
| Emd Serono, INC. | $28.66 | 2024 | |
| Sumitomo Pharma America, INC. | $23.67 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $22.25 | 2019 | |
| Horizon Therapeutics Plc | $18.82 | 2023 | Krystexxa |
| Baxter Healthcare | $18.40 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Mannkind Corporation | $17.88 | 2020 | |
| Amarin Pharma, INC. | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.